Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP951568priorityCriticalpatent/ECSP951568A/en
Publication of ECSP951568ApublicationCriticalpatent/ECSP951568A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se describe un compuesto de la fórmula: en donde Z es un grupo tetrahidro-pirano, seleccionado a partir de: que se refiere a nuevos derivados de sordarina que tienen actividad antifungal, a procesos para su preparación, a composiciones farmacéuticas que los contienen y a su uso en medicina, en forma más particular, en la prevención o tratamiento de enfermedades en animales, incluyendo humanos, provocadas por la infección fungal.A compound of the formula is described: wherein Z is a tetrahydro-pyran group, selected from: referring to new sordarine derivatives having antifungal activity, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine, more particularly, in the prevention or treatment of diseases in animals, including humans, caused by fungal infection.
Compound, processes for preparing a compound, for treating or preventing diseases of the endocrine system and for the manufacture of a drug, pharmaceutical composition, and, use of a compound
Compound, pharmaceutical composition, use of the compound, and, processes for the treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound
Compound, use thereof, pharmaceutical composition, and, processes for treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound.
TRICYCLIC UREA COMPOUNDS USEFUL FOR THE INHIBITION OF THE FUNCTION OF PROTEIN G AND FOR THE TREATMENT OF PROTEOLYTIC DISEASES, PHARMACEUTICAL COMPOSITION, AND THE USE OF THE SAME FOR THE PREPARATION OF MEDICINES.
LACTACISTIN ANALOG COMPOUNDS, METHOD FOR INHIBITING PROTEASOMA-DEPENDENT PROTEOLYSIS, METHOD FOR IDENTIFYING A PROTEOLISIS-MEDIATED BIOLOGICAL PROCESS, USE OF SUCH COMPOUNDS BY A PROAROID DRUG TO PREPARE A MEDICINAL PRODUCT
Compound, use of it, pharmaceutical composition, and processes for the treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound
Compound, pharmaceutical composition, method of treating or preventing disease, method for enhancing cognition in a healthy patient, and use of a compound
BENZOILGUANIDINES REPLACED WITH HETEROCICLOS-N-OXIDES, PROCEDURE FOR THEIR PREPARATION, ITS USE AS A MEDICINAL OR DIAGNOSTIC AGENT, AS WELL AS A MEDICATION THAT CONTAINS THEM.